ArticleOncology letters2026
Pathological response and tumor regression grading following neoadjuvant chemo-immunotherapy and chemotherapy in resectable non-small cell lung cancer.
Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Recent neoadjuvant trials in lung cancer have demonstrated meaningful survival advantages, highlighting the need for standardized assessment of pathologic response in resected specimens. Only two systems are currently recommended for evaluating post-treatment response, namely the International Association for the Study of Lung Cancer (IASLC) tumor regression grading system and the immune-related pathologic response criteria (irPRC). The present study aimed to review and apply histopathologic parameters for assessing tumor regression in non-small cell lung carcinoma (NSCLC) specimens resected after neoadjuvant therapy. A total of 30 NSCLC resections obtained after neoadjuvant therapy between 2022 and 2025 were analyzed. Gross and microscopic evaluations were performed according to IASLC recommendations. Residual viable tumor, fibrosis, inflammation and necrosis were semi-quantitatively assessed according to IASLC and irPRC principles. Major pathologic response (mPR) was defined as ≤10% viable tumor and pathologic complete response (pCR) as 0% viable tumor. Associations with demographic features, treatment modalities and survival outcomes were analyzed. Compared with chemotherapy (CT) alone, chemo-immunotherapy (CIT) exhibited a trend toward a deeper pattern of tumor regression, reflected by lower median viable tumor percentages (7.5 vs. 55.0%) and higher mPR rates (62.5 vs. 22.7%), although these differences did not reach statistical significance. pCR occurred in 37.5% of patients treated with CIT and in 13.6% of patients treated with CT. CIT specimens demonstrated more prominent immune-mediated stromal changes, including greater intratumoral inflammation (32.5 vs. 10.0%) and more frequent lymphocytic patterns. Fibrosis strongly correlated with response (P<0.001), whereas necrosis did not. Spread through air spaces positivity was found to be significantly reduced in cases of mPR (P<0.001). Therefore, neoadjuvant CIT may be associated with deeper pathologic regression compared with CT, characterized by increased fibrosis and immune activation. Major pathologic response remains a potential prognostic indicator and integration of IASLC and irPRC criteria, together with tumor microenvironment assessment, may improve the evaluation of treatment response in resectable NSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.